Erasca Hit With Securities Class Action After $2.8B Market Cap Loss
A securities fraud lawsuit alleges Erasca misled investors about IP and drug safety, triggering a 48% stock drop. Investors have until August 10, 2026 to seek lead plaintiff status.
Legal entity
RMC-6236
Productcorporate-law is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ERAS-0015, the most common co-covered peer. We currently track 1 Legal story that mention RMC-6236, all published on June 16, 2026.
Last mentioned: Jul 7, 2026
Entity pulse
Recent coverage · RMC-6236
1 story
avg impact
0% positive
100% negative
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
What the coverage shows about RMC-6236
corporate-law is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ERAS-0015, the most common co-covered peer. We currently track 1 Legal story that mention RMC-6236, all published on June 16, 2026. Each carries 2 original sources on average.
- Stories tracked
- 1
- Sources per story
- 2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering RMC-6236. Shared-story counts are live from our verified record — not editorial picks.
Timeline
-
Lead Plaintiff Deadline
Deadline for investors to move for appointment as lead plaintiff in the securities class action.
-
Securities Class Action Announced
Hagens Berman announces the filing of a federal securities class action lawsuit and begins soliciting investor clients.
-
Stock Crash and Corrective Disclosure
Erasca shares plunge 48% on news that Revolution Medicines accused the company of patent infringement and that a trial patient died a month after receiving ERAS-0015. Class period ends.
-
Alleged Misleading Statements
Erasca reportedly assured investors of ERAS-0015's IP protection and made dose-equivalence comparisons to RevMed's RMC-6236.
-
Class Period Begins
Start of the period during which Erasca allegedly made misleading statements that inflated its stock price.
Stories mentioning RMC-6236 1
RMC-6236 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.